Lonza Group (OTCMKTS:LZAGY) Lowered to “Strong Sell” Rating by Zacks Research

Lonza Group (OTCMKTS:LZAGY) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports.

Lonza Group Price Performance

OTCMKTS LZAGY opened at $66.36 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.87 and a current ratio of 1.46. Lonza Group has a twelve month low of $55.57 and a twelve month high of $73.85. The stock has a fifty day simple moving average of $68.23 and a 200 day simple moving average of $68.67.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.